G protein-coupled receptors, usually shortened to GPCRs, are a massive family of proteins embedded in cell membranes that act as the body’s primary communication relays. They detect signals on the outside of a cell and trigger responses on the inside, governing everything from how you see light and smell food to how your heart rate adjusts and how medications take effect. Roughly 800 GPCRs are encoded in the human genome, and about 34% of all FDA-approved drugs work by targeting them, making this single protein family more pharmaceutically important than any other.1Cell. Pharmacogenomic Landscape of GPCR Drug Targets Understanding what they are, how they work, and why they keep showing up in medical research is worth the time.
What GPCRs Actually Do
Picture a protein that snakes back and forth through the outer membrane of a cell seven times, forming a bundle of helices. The part that sticks out of the cell is shaped to grab onto a specific molecule, whether that is a hormone, a neurotransmitter, a smell molecule, or even a photon of light. The part inside the cell is designed to interact with a G protein, a small molecular switch that sits just beneath the membrane waiting to be activated.
When the right signal molecule (called a ligand) binds to the receptor’s outer face, the receptor changes shape. That shape change nudges the G protein on the inner side, causing it to split into active pieces that then fan out and trigger a cascade of events inside the cell. Those events might include releasing calcium stores, switching genes on or off, altering how fast the cell grows, or adjusting ion channels that control electrical signals. The cell’s eventual response depends on which receptor was activated, which G protein it couples to, and what downstream machinery is available in that particular cell type.
The Five Major Families
Not all GPCRs look or behave the same. A large-scale analysis of the human genome grouped them into five main families, known by the acronym GRAFS: glutamate, rhodopsin, adhesion, frizzled/taste2, and secretin.2Molecular Pharmacology. The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints The rhodopsin family is by far the largest, containing the majority of the receptors that detect hormones, neurotransmitters, and sensory stimuli. It subdivides further into at least 13 branches.
The adhesion family is distinctive because its members have unusually large extracellular regions studded with diverse protein-binding domains, allowing them to sense components of the tissue environment and the extracellular matrix. There are 33 adhesion GPCRs in humans, each with unique expression patterns and physiological roles.3PubMed Central. Adhesion G protein-coupled receptors: structure, signaling, physiology, and pathophysiology A hallmark of these receptors is a built-in self-cleavage domain called a GAIN domain, which can split the receptor into two fragments that remain physically associated until the right mechanical or chemical cue separates them and triggers signaling.4PubMed Central. Emerging roles of adhesion G protein-coupled receptors The glutamate, secretin, and frizzled/taste2 families are smaller but critically involved in brain signaling, metabolic hormone sensing, and developmental patterning, respectively.
How Your Senses Rely on GPCRs
Two of your most immediate senses run almost entirely on GPCR signaling. Vision depends on rhodopsin, a GPCR in the rod cells of your retina that responds to photons. When light hits rhodopsin, it changes shape and activates its partner G protein, transducin, kicking off a chain reaction that converts a physical stimulus into an electrical nerve impulse.5PubMed Central. Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening Rhodopsin was the first GPCR to have its three-dimensional structure solved and has served as a template for understanding the entire superfamily.
Smell works on a similar principle, just with far more variety. Olfactory neurons in your nose express hundreds of distinct odorant receptors, each a GPCR tuned to a different range of airborne chemical shapes. The discovery that odorant detection uses a specialized family of GPCRs coupled to an enzyme cascade to produce its signals highlighted how versatile this receptor design can be.6PubMed. G proteins and olfactory signal transduction Taste perception of sweet, bitter, and umami flavors also relies on GPCRs, specifically members of the glutamate and taste2 receptor families.
GPCRs in Metabolism and Hormonal Control
Beyond the senses, GPCRs manage a huge range of hormonal and metabolic processes. One of the most medically relevant examples right now is the GLP-1 receptor, a GPCR that has become the target of blockbuster weight-loss and diabetes drugs such as semaglutide. The GLP-1 receptor sits on pancreatic beta cells and, when activated by the gut hormone GLP-1, boosts insulin release. Critically, the receptor only enhances insulin secretion when blood sugar is already elevated, which is why GLP-1-based drugs reduce blood glucose with a lower risk of dangerously low blood sugar compared to older therapies.7PubMed Central. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence The GLP-1 receptor is increasingly understood to organize complex signaling hubs within the cell that extend well beyond simple “on-off” switches.8JCI Insight. Signaling architecture of the glucagon-like peptide-1 receptor
Similar GPCR-driven hormone systems control thyroid function, blood pressure, reproductive hormones, and stress responses through cortisol. Inherited mutations that make these receptors permanently active or inactive cause a range of endocrine disorders. Over 100 gain-of-function mutations across at least ten GPCR genes have been linked to human endocrine diseases alone.9PubMed. Gain-of-function mutations in G-protein-coupled receptor genes associated with human endocrine disorders Loss-of-function mutations in GPCR genes have been identified as causes of retinal, metabolic, and developmental disorders as well.10PubMed. Inherited diseases involving g proteins and g protein-coupled receptors
Why So Many Drugs Target GPCRs
An estimated 700 approved drugs work by binding to GPCRs, which means GPCRs account for the largest family of proteins targeted by pharmaceuticals.11PubMed Central. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? Beta-blockers for heart disease, antihistamines for allergies, opioids for pain, antipsychotics for schizophrenia, and the GLP-1 agonists for diabetes and obesity are all GPCR-targeted drugs. The oft-cited figure that “30% or more” of all approved drugs target GPCRs has been a staple of pharmacology textbooks, though a recent analysis questioned whether that proportion holds consistently across all regulatory agencies and time periods.12PubMed Central. Do GPCRs constitute the target of 30% of newly approved drugs in Germany? The ballpark remains impressive regardless: GPCRs and their associated signaling proteins represent roughly 17% of all protein targets for approved drugs, with GPCRs themselves making up about 12%.13PubMed Central. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
The reason they make such good drug targets is partly structural. Their ligand-binding pockets are accessible from outside the cell, making them relatively easy for drug molecules to reach. And because each receptor triggers a specific set of downstream effects, activating or blocking the right one can produce a focused therapeutic result. The challenge, as we will see, is that “focused” is a relative term when the same receptor can activate multiple pathways at once.
Biased Signaling and the Quest for Smarter Drugs
For decades, pharmacology treated GPCRs as simple on-off switches: a drug either turned the receptor on (agonist) or blocked it (antagonist). That model started breaking down as researchers discovered that the same receptor, when hit by different drugs, could preferentially activate one internal pathway while leaving another quiet. This concept, now called biased agonism, has reshaped how new drugs are designed.14PubMed Central. G Protein-coupled Receptor Biased Agonism
GPCRs signal through two broad routes. One runs through G proteins themselves, and the other runs through proteins called beta-arrestins, which were originally discovered as molecules that shut GPCR signaling down but turned out to have their own independent signaling roles.15PubMed Central. G Protein-Coupled Receptor Signaling Through β-Arrestin-Dependent Mechanisms A biased ligand can favor the G protein pathway over the beta-arrestin pathway, or vice versa. Because the two pathways often produce different biological effects, designing a ligand that selectively activates just the beneficial pathway could, in theory, deliver a drug’s desired effects while reducing its side effects.16PubMed. Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential
The underlying reason biased signaling is possible comes down to the physical flexibility of the receptors themselves. GPCRs are not rigid locks that snap into one “active” conformation. They constantly fluctuate among many shapes, and different ligands shift the balance toward different clusters of those shapes, which in turn present different faces to the intracellular signaling machinery.17Europe PMC / Trends in Cell Biology. Conformational Basis of G Protein-Coupled Receptor Signaling Versatility There are also inverse agonists, drugs that bind to a receptor and actively suppress its baseline activity rather than just blocking incoming signals. These work by stabilizing a distinct inactive conformation of the receptor that differs from what an agonist produces.18PubMed. Molecular basis of inverse agonism in a G protein-coupled receptor
An additional layer of complexity comes from allosteric modulators, molecules that do not compete directly with a receptor’s natural ligand but instead bind at a different site on the receptor and tweak its behavior. Some boost the natural ligand’s effect, some dampen it, and some change the character of the signaling altogether. Allosteric sites have been identified across multiple GPCR classes and are being explored as drug targets because they offer a way to fine-tune a receptor’s response rather than simply switching it on or off.19Nature Communications. Allosteric modulators enhance agonist efficacy by increasing the residence time of a GPCR in the active state
Signaling Does Not Stop at the Cell Surface
A long-held assumption was that GPCRs did their signaling work at the outer membrane and were then pulled inside the cell for recycling or disposal. That view has been overhauled. Research over the past fifteen years has shown that many GPCRs continue signaling after they have been internalized into compartments called endosomes, and that the signals produced from these internal locations can differ from those generated at the cell surface.20Trends in Biochemical Sciences. Endomembrane GPCR signaling
The concept of “location bias” adds yet another dimension to GPCR pharmacology. When the same receptor generates its second-messenger signals from the cell surface versus from an endosome, the downstream gene-activation programs can look quite different. One striking example involves a receptor involved in pain signaling: its activity at the surface produces an acute pain sensation, while its continued signaling from endosomes drives sustained, chronic pain.21PubMed Central. Location Bias as Emerging Paradigm in GPCR Biology and Drug Discovery Similarly, beta-arrestin-mediated signaling events showed much larger ligand-dependent variation at endosomes than at the plasma membrane, indicating that functional selectivity between drugs is amplified by where in the cell the receptor happens to be working.22PubMed. G protein-coupled receptor endocytosis generates spatiotemporal bias in β-arrestin signaling
This has practical implications for drug design. If a drug’s side effects come from signaling that happens at a specific cellular location, it might be possible to engineer molecules that activate the receptor in one compartment but not another, separating therapeutic effects from unwanted ones more precisely than biased agonism alone can achieve.
How Receptors Talk to Each Other
GPCRs do not always work as lone operators. There is strong evidence that many of them form pairs or small clusters, either with copies of themselves (homodimers) or with different receptor types (heterodimers). When two different GPCRs come together, they can change each other’s behavior in ways that neither receptor exhibits alone, altering which ligands bind, how strongly they signal, and how quickly they are pulled off the cell surface.23PubMed Central. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function Homodimerization appears to play a role in quality control, helping the cell check that a receptor is properly folded before sending it to the membrane.24PubMed. G protein-coupled receptor dimerisation: molecular basis and relevance to function
From a drug-development standpoint, heterodimer pairs are tantalizing. If a specific combination of two receptors exists predominantly in one tissue, a drug designed to target that pair could achieve tissue selectivity that is impossible when targeting either receptor individually. Some clinically effective drugs are already thought to work, at least partly, through modulating GPCR heterodimers, though pinning down which pairs matter most in living patients remains an active area of research.
The Lipid Environment Matters Too
GPCRs do not float in a featureless membrane. The fats surrounding them actively influence how they behave. Large-scale molecular simulations have shown that all GPCRs interact closely with membrane lipids, especially cholesterol and a class of signaling lipids called phosphoinositides. The number, location, and strength of these lipid interactions vary by receptor and even by the receptor’s active or inactive state.25Biophysical Journal. GPCR-Lipid Interactions Focus on a Diverse Lipid Landscape Cholesterol nestles into grooves between the receptor’s transmembrane helices through hydrophobic contacts, while phosphoinositides grab onto charged residues on the intracellular loops through electrostatic attraction. Because membrane composition varies between cell types and even between different regions of the same cell, this lipid sensitivity gives the cell another way to tune GPCR behavior without changing the receptor or its ligand.
Orphan Receptors and Untapped Drug Targets
Despite decades of research, a substantial fraction of GPCRs in the human genome remain “orphans,” meaning their natural ligands and physiological roles are still unknown. These orphan GPCRs are considered high-potential targets for new drugs, but finding out what activates them has been slow going.26PubMed. Maximizing serendipity: strategies for identifying ligands for orphan G-protein-coupled receptors Traditional approaches that screen thousands of candidate molecules against a receptor in a test tube have yielded diminishing returns over time, prompting a push toward newer methods.27PubMed Central. Identifying ligands at orphan GPCRs: current status using structure-based approaches
One notable innovation is an open-source platform called PRESTO-Tango, which allows researchers to test drug-like molecules against essentially the entire non-olfactory human GPCR collection in parallel. The system uses a beta-arrestin-recruitment assay, meaning it detects receptor activation through a G-protein-independent route, and it has already been validated at over 120 known GPCR targets while also being used to identify new ligands for orphan receptors.28PubMed Central. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome If even a fraction of the remaining orphan GPCRs turn out to be medically important, the reservoir of undiscovered drug targets is enormous.
How Structural Biology Cracked Them Open
For a long time, researchers knew GPCRs were important but could not see what they looked like in atomic detail. The breakthrough came in stages. In the 1980s, Robert Lefkowitz and Brian Kobilka cloned the first GPCR gene, the beta-2 adrenergic receptor. Two decades later, Kobilka’s team solved its crystal structure, a technical feat that earned both scientists the 2012 Nobel Prize in Chemistry.29PubMed. Advances in the investigation of structure and function of G protein-coupled receptors (by awarding the Nobel Prize for Chemistry in 2012 to Robert Lefkowitz and Bryan Kobilka) That work also established methods for purifying and crystallizing other membrane receptors, opening the floodgates.
More recently, cryo-electron microscopy has taken over as the go-to technique. Optimized workflows now allow GPCR structures to be routinely determined at resolutions better than 2.5 angstroms, sharp enough to see where individual atoms sit and how drug molecules nestle into binding pockets.30Nature Communications. Routine sub-2.5 Ã… cryo-EM structure determination of GPCRs Cryo-EM has also captured GPCRs in the act of coupling to their G proteins within a lipid membrane environment, rather than in detergent, revealing a more extensive network of protein-protein contacts than earlier structures suggested.31PubMed Central. Cryo-EM structure of an activated GPCR-G protein complex in lipid nanodiscs Each new structure feeds directly into drug design, because knowing exactly where a molecule binds lets chemists tweak its shape to improve potency or selectivity.
AI-Driven Drug Discovery
Artificial intelligence is accelerating GPCR research on multiple fronts. AI-based tools are being used for predicting receptor structures, screening virtual libraries of millions of candidate drug molecules, and even generating entirely new molecular designs. The pace picked up sharply between 2023 and 2025, and the broader recognition of AI’s impact on protein science was underscored by the 2024 Nobel Prize in Chemistry.32PubMed Central. Computer-aided structural modeling and drug discovery for G-protein-coupled receptors in the age of artificial intelligence
A recent benchmarking study tested several deep-learning tools, including AlphaFold 2, AlphaFold 3, and others, on their ability to predict how peptide ligands bind to GPCRs. The top-performing structure-aware model achieved strong classification accuracy in distinguishing true binders from decoys across a test set of over a thousand candidates.33Briefings in Bioinformatics. Deep learning in GPCR drug discovery: benchmarking the path to accurate peptide binding These results suggest that computational screening can reliably narrow down which molecules are worth testing in the lab, potentially cutting years and millions of dollars from the traditional drug-discovery pipeline.
GPCRs in the Brain and Mental Health
Many of the neurotransmitter systems implicated in psychiatric disorders signal through GPCRs. Serotonin receptors, dopamine receptors, glutamate receptors, and a range of neuropeptide receptors are all GPCRs, and dysfunction of these receptors in the frontal cortex and limbic regions is thought to underlie the cognitive, perceptual, mood, and motor symptoms seen in conditions like depression, schizophrenia, and anxiety disorders.34PubMed Central. G protein-coupled receptors in major psychiatric disorders Most existing psychiatric medications, including SSRIs, antipsychotics, and benzodiazepines, act directly or indirectly on GPCR pathways. The hope is that a deeper understanding of biased signaling and receptor dimerization could eventually lead to psychiatric drugs that are more targeted, with fewer of the metabolic and neurological side effects that limit current treatments.
An Ancient Signaling System
GPCRs are not a recent evolutionary invention. Most of the gene families involved in GPCR signaling were already present in the last common ancestor of all eukaryotes, meaning they predate the split between animals, plants, and fungi by well over a billion years. Even more strikingly, the single-celled ancestor of all animals already possessed all the G protein subunit types typical of modern multicellular organisms.35PubMed Central. The Evolution of the GPCR Signaling System in Eukaryotes: Modularity, Conservation, and the Transition to Metazoan Multicellularity Fused GPCR-enzyme proteins have been found sporadically across nearly all major branches of eukaryotic life except plants, and phylogenetic analysis suggests these hybrid proteins trace back to the earliest eukaryotes, pointing to an ancestral system where environmental sensing and intracellular response were directly linked within a single protein.36PubMed Central. The Ancient Link between G-Protein-Coupled Receptors and C-Terminal Phospholipid Kinase Domains The GPCR design proved so useful that evolution kept elaborating on it, generating hundreds of specialized versions in vertebrates through repeated gene duplication and domain shuffling rather than inventing something new from scratch.
Receptor Trafficking Is More Complicated Than Expected
Once activated, a GPCR is typically pulled off the cell surface through a process called internalization, which was long thought to depend heavily on beta-arrestins binding to the receptor and escorting it into the cell. Recent work on the GLP-1 receptor has challenged that assumption. Experiments in cells engineered to lack both beta-arrestin proteins showed that the GLP-1 receptor internalized at the same rate regardless, and that the process instead depended on a different protein complex, AP2, binding directly to the receptor’s intracellular tail.37Nature Communications. Multi-faceted roles of β-arrestins in G protein-coupled receptor endocytosis When AP2 was knocked down, internalization was strongly inhibited in both normal cells and beta-arrestin-deleted cells.
This finding matters because the way a receptor is internalized affects how long it signals, where it signals from, and how quickly the cell can recycle it back to the surface or degrade it. If different receptors use different internalization routes, then drugs designed to manipulate trafficking need to be tailored to the specific receptor rather than relying on a one-size-fits-all model. The GLP-1 receptor result is a reminder that general rules in GPCR biology often come with large receptor-specific exceptions, and that drug developers ignore those exceptions at their peril.